Skip to content Skip to footer

The Calmer Co International Ltd

Share Price and News

ASX BIG FOUR - LIVE SNAPSHOT

SELL

Whitehaven Coal

(ASX:WHC)

Paul Flynn
01/03/2026
$8.7m
BUY

Elixir Energy

(ASX:EXR)

Featured
SELL

Aspen Group

(ASX:APZ)

David Dixon
03/03/2026
$11.4m
BUY

Lovisa

(ASX:LOV)

Brett Blundy
04/03/2026
$6.8m
Copmany Overview

The Calmer Co

The Calmer Co International Ltd is a consumer-driven company focused on delivering high-quality wellness and self-care products to the market, particularly kava. Kava is a beverage in the South Pacific derived from Indigenous plants. It has traditionally been confined to the Pacific Islands but has been growing in popularity around the world because of its sedative, anaesthetic and euphoriant properties. It has grown in popularity for many reasons including destigmatisation of it in Western countries, growing awareness about mood and health benefits that can be derived from it not to mention the lifting of long-standing prohibitions on imports. With an expanding presence in both domestic and international markets, The Calmer Co is well-positioned to capitalise on the rising demand for wellness products. Its commitment to quality and innovation sets it apart from its competitors, making it a strong contender in the wellness sector.

Calmer Co's History

Founded with the vision of creating wellness products that address the increasing need for relaxation and mental health support, The Calmer Co has made significant strides in a short time. The company was established in Australia and listed in 2018. Initially it did not have success because its original approach was to focus efforts on attempting to sell Fiji Kava products via Chinese cross border channels, coupled with unprofitable sales at Chemist Warehouse in Australia under a distribution agreement announced in April 2021. But things have improved in the past few years through several initiatives that focused on profitable sales and distribution agreements, not to mention increased product innovation and liberalisation. Until December 2021, the company was only able to import products as complimentary medicines, but it obtained approval to import drinking kava into Australia under the Kava Pilot Importation Program facilitated by DFAT. The company’s recent major milestones include partnerships with retail giants and a strategic focus on international markets, particularly in Asia and North America. With these key developments, The Calmer Co has been able to diversify its revenue streams and build a more resilient business model. Moving forward, its focus on expanding its product lines and maintaining high standards of quality positions it for continued growth.

Get Our Full ASX Stock Analysis Report

Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.

Forward View

Future Outlook of The Calmer Co International (ASX: CCO)

Looking ahead, the future outlook for The Calmer Co appears promising, driven by several key factors. These include that the global wellness industry is on an upward trajectory, and the liberalisation of kava globally. CCO is well positioned to benefit as it expands globally. The challenge is that the company is still loss-making and is considered a ‘penny stock’ with a share price of less than 1c – giving rise to the perception that it is risky.

Our Assessment

Is Calmer Co (ASX: CCO) a Good Stock to Buy?

Whether The Calmer Co (ASX: CCO) is a good stock to buy depends on various factors, including its valuation, growth potential, and risk profile. The company has strong potential with its market position. However, the kava industry remains nauseant outside the South Pacific and there remains some stigmatisation of it. Moreover, the company will need to become profitable eventually and even though strides have been made, it is proving difficult. So for the time being, CCO would only be a good stock to buy for the most risk-averse investors.

Our Stock Analysis

Weebit Nano (ASX:WBT) Q3 shows the royalty model taking shape

Royalty revenue moves closer after Q3 Weebit Nano is one of our favourite stocks and…

Nanoveu (ASX:NVU) 16nm chip enters TSMC fabrication, A$7.5m raise funds the validation push

Design completion is not the milestone that moves a semiconductor company from interesting to credible.…

DorsaVi (ASX:DVL) Ultra Edge AI Could Unlock a Re-Rate Toward Our Base Valuation

DorsaVi (ASX:DVL) holds two IP acquisitions in ReRAM and neuromorphic AI. We value the stock…

Celestica (NYSE:CLS) The AI Infrastructure Winner No One Wanted This Quarter

Celestica (NYSE:CLS) posted 53% revenue growth and a record 8% margin in Q1 2026, but…

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

The 50% CGT discount on shares is one of the key mechanisms that helps investors…

Apple’s New Era: What the Tim Cook to John Ternus Transition Means for the World’s Most...

Apple (NASDAQ: AAPL) has confirmed that Tim Cook will step down as chief executive officer…
Faq

Frequently Asked Questions

What is the dividend yield of The Calmer Co International Ltd?
The Calmer Co currently does not offer a high dividend yield as the company is focused on reinvesting its profits to fuel growth and expansion. However, dividends may be considered in the future as the company matures.
Compared to its competitors, The Calmer Co stands out for its strong focus on product innovation and quality. While it operates in a competitive space, its expanding international footprint and commitment to premium products position it well for long-term success.
The primary risks include market competition, supply chain disruptions, and changes in consumer preferences. Investors should also consider the company’s reliance on global expansion and its ability to scale operations efficiently.
The growth potential of CCO is significant, driven by the rising global demand for wellness products. Its strategic expansion into international markets, particularly in Asia and North America, provides ample opportunities for revenue growth.
Given its potential for growth and the increasing global interest in wellness, CCO could be considered a strong long-term investment. However, its success depends on the company’s ability to innovate, manage competition, and effectively expand its market presence.

Stay Sharp on the ASX

Weekly research. Independent analysis. No noise.

Free forever · Unsubscribe anytime

© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here